1Cova D , De Angelis L , Giavarini F , et al. Pharmacokinetics and metabolism of oral diosmin in healthy volunteers [ J ]. Int J Clin Pharmacol Ther Toxicol, 1992,30( 1 ) : 29-33.
2Lyseng-Williamson KA, Perry CM .Micronised purified flavon- old fraction:a review of its use in chronic venous in suffi- ciency , venous ulcers and haemorrhoids [ J ] . Drags , 2003 , 63(1):71-100.
3Ramelet AA. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency [J]. Angiology, 2001 , 52(Suppl 1 ) : S49-S56.
4Smith PD. Neutrophil activation and mediators of inflammation in chronic venous insuffi-ciency[J] .J Vase Res, 1999, 36 (Suppl 1 ) : 24-36.
5Bergan JJ, Schmid-Sehonbein GW, Takase S .Therapeutic ap- proach to chronic venous insufficiency and its complications: place of Daflon 500 mg[J].Angiology, 2001 , 52 (Suppl 1 ): S43-S47.
6Le Devehat C, Khodabandehlou T, Vimeux M, et al. Evalua- tion of haemorheological and microcireulatory disturbanees in chronic venous insufficiency:activity of Daflon 500 rag[J]. Int J Microcirc Clin Exp, 1997,17(Suppl 1):27-33.
7Labrid C. Pharmacologic properties of Daflon 500 mg [ J ]. An- giology, 1994,45 ( 2 ) : 524-530.
8Ramelet AA. Pharmacologic aspects of a phlebotropic drug in CVI-associated edema[J]. Angiology, 2000 , 51 ( 1 ) : 19-23.
